Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors.

BACKGROUND AND PURPOSE The primary objectives of this study were to address two major questions. (1) Does VEGF receptor-2 antibody (DC101) produce detrimental effects on tumor vascular function and oxygenation that could compromise adjuvant therapies? (2) Is pathophysiological response to such antiangiogenic strategies different in transplanted versus primary spontaneous tumors? MATERIALS AND METHODS The effects of early and late initiation DC101 treatment were evaluated using spontaneous murine mammary carcinomas and two markedly different transplanted mammary tumors, MCa-35 and MCa-4. Mice were administered DC101 or saline, tumors were frozen, and immunohistochemical staining was quantified using image analysis of multiply-stained frozen sections. Total blood vessels were identified using antibodies to CD31 or panendothelial antigen, perfused vessels via i.v. injection of fluorescent DiOC7, and tumor hypoxia by hypoxia marker (EF5) uptake. RESULTS Tumor growth was significantly inhibited following DC101 administration in all tumor models. In general, early initiation DC101 treatment reduced perfused vessel counts and increased tumor hypoxia, while late initiation treatment had no significant impact on either. Results indicate that DC101 slows tumor growth through a decrease in vascular function, leading to increased tumor cell apoptosis and necrosis at sites distant from perfused blood vessels, and suggest that DC101 accelerates the rate at which tumor cells outgrow their functional vascular supply. CONCLUSIONS Although highly variable among individual spontaneous tumors, the overall effects of DC101 on tumor hypoxia were quite similar between spontaneous and transplanted tumors. Since reductions in tumor oxygenation due to antiangiogenic treatment were transient, initial pathophysiological deficiencies that could compromise conventional therapies over the short-term may be of less relevance when administered over more extended treatment schedules.

[1]  L. Ellis,et al.  Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice , 2002, International journal of cancer.

[2]  Michael D Feldman,et al.  Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. , 2003, The American journal of pathology.

[3]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[4]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[5]  J. Cherrington,et al.  The Antiangiogenic Agents SU5416 and SU6668 Increase the Antitumor Effects of Fractionated Irradiation , 2002, Radiation research.

[6]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[7]  M. Stuschke,et al.  Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: Potentiation by irradiation , 2003, International journal of cancer.

[8]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[9]  Donald W Kufe,et al.  Vascular Endothelial Growth Factor Enhances Endothelial Cell Survival and Tumor Radioresistance , 2002, Cancer journal.

[10]  Jean-Luc Balligand,et al.  Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. , 2003, Cancer research.

[11]  L. Ellis,et al.  Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.

[12]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[13]  R. Weichselbaum,et al.  Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. , 2003, Cancer research.

[14]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[15]  L. Ellis,et al.  Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. , 2001, International journal of oncology.

[16]  E M Lord,et al.  Effects of Radiation on Tumor Intravascular Oxygenation, Vascular Configuration, Development of Hypoxia, and Clonogenic Survival , 2001, Radiation research.

[17]  P. Olive,et al.  Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. , 1989, British Journal of Cancer.

[18]  A. Orucevic,et al.  Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice , 1997, International journal of cancer.

[19]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[20]  B. Fenton,et al.  Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. , 2003, International journal of radiation oncology, biology, physics.

[21]  M. Feldman,et al.  Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. , 2002, Cancer research.

[22]  R. Jain.  Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.

[23]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[24]  R. Jain,et al.  Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. , 2003, Cancer research.

[25]  B. Fenton,et al.  Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis , 2002, British Journal of Cancer.

[26]  Y. Kakeji,et al.  Influence of an anti‐angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy , 1995, International journal of cancer.

[27]  V. Dixit,et al.  Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[28]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[29]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[30]  P Vaupel,et al.  Modulation of tumor oxygenation. , 1998, International journal of radiation oncology, biology, physics.

[31]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[32]  B. Fenton,et al.  Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements , 1999, British Journal of Cancer.

[33]  J. Green,et al.  Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. , 2000, Cancer research.

[34]  P. Musiani,et al.  Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. , 2000, Cancer research.

[35]  J. Cherrington,et al.  Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. , 2002, Cancer research.

[36]  L. Harwell,et al.  Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. , 1993, Cancer research.

[37]  R. Jain,et al.  Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. , 2000, Cancer research.